Back to Dashboard

ZE46-0134-0002-US

AML-MDS•ZE46-0134-0002-US•Last updated: 2/17/2026
Recruiting

Study Design

Study Drug

ZE46-0134

Mechanism of Action

FLT3 inhibitors

Sponsor

Unknown

Design

I

Control Arm

-

Criteria

Inclusion Criteria

Group 1: FLT3 ITD/TDK mutation Group 2: Spliceosome Mutation (SF3B1, SRSF2, U2AF1, ZRSR2)

Age: ≥18 years Phase: I

Exclusion Criteria

Enrollment

Progress0 / 0

Contact Information

Principal Investigator

Unknown

Study Nurse

李佳玲

Contact Tel

4620